Holen Sie sich die Stockscreener-App
14.88
0.40%
-0.06
Handel nachbörslich:
14.88
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.94
Offen:
$14.9
24-Stunden-Volumen:
1.20M
Relative Volume:
0.61
Marktkapitalisierung:
$13.22B
Einnahmen:
$3.85B
Nettoeinkommen (Verlust:
$667.93M
KGV:
22.65
EPS:
0.657
Netto-Cashflow:
$142.30M
1W Leistung:
-4.00%
1M Leistung:
+0.95%
6M Leistung:
-5.04%
1J Leistung:
-2.26%
1-Tages-Spanne:
$14.81
$14.95
1-Wochen-Bereich:
$14.81
$15.56
52-Wochen-Spanne:
$12.26
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.88 | 13.22B | 3.85B | 667.93M | 142.30M | 0.657 |
|
RGC
Regencell Bioscience Holdings Ltd
|
10.36 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.08 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.26 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.42 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Asian ADRs Climb With North And South Leaders - Finimize
Dr Reddys Laboratories allots Equity shares - Business Standard
RDY’s Market Whiplash: 2.41% YTD Rise, 14.68% Rise in 30 Days - investchronicle.com
Stocks Showing Rising Market Leadership: Dr. Reddy's Labs ADR Earns 81 RS Rating - Investor's Business Daily
Yatsen And Zai Lab Shine As Asian ADRs Climb In The US - Finimize
HSBC Upgrades Dr. Reddy’s Laboratories Limited (RDY) to Buy from Hold - Insider Monkey
Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech By Investing.com - Investing.com Nigeria
Dr. Reddy’s stock rises on biosimilar collaboration with Alvotech - Investing.com Australia
HSBC upgrades Dr. Reddy’s stock rating citing semaglutide prospects - Investing.com
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - GlobeNewswire Inc.
LLY Stock Quote Price and Forecast - CNN
Asian Equities Gain In US Markets' Positive Start - Finimize
Dr. Reddy’s Laboratories Receives USFDA Observations After Recent Inspection - TipRanks
Dr Reddys Laboratories shares climb over 1.1% amid increased trading volume in today's session - Moneycontrol
Axa S.A. Has $1.23 Million Holdings in Dr. Reddy's Laboratories Limited (NYSE:RDY) - MarketBeat
Indian ADRs Surge in US Markets as Wall Street soars after US-China trade talks - Moneycontrol
Shares To Buy For Short-term: Analysts recommend 5 largecap, 2 midcap stocks; Britannia, Dr Reddy's, TCS on the list - Zee Business
Wells Fargo & Company MN Has $124,000 Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) - Defense World
Asian Equities Climb Despite Weekly Losses - Finimize
Dr. Reddy’s Earnings: Year-End Numbers Look Solid as Demand and Prescription Trends Remain Resilient - Morningstar
Dr. Reddy’s Laboratories Grants Stock Options to Employees in May 2025 - TipRanks
Insider’s View: Deciphering Six Flags Entertainment Corp (FUN)’s Financial Health Through Ratios - DWinneX
Balance Sheet Breakdown: Astrazeneca plc ADR (AZN)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Ratio Examination: Dr. Reddy’s Laboratories Ltd. ADR (RDY)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Financial Analysis: Spotify Technology S.A (SPOT)’s Ratios Unveil Key Insights - DWinneX
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - Trade Brains
Q4 Results Highlights: Dr. Reddy's Laboratories profit rises 22% YoY to ₹1,594 crore, dividend recommended - Upstox
Indian Markets Set for Bloody Friday as Gift Nifty Signals Sharp Gap-Down Open Amid Escalating India-Pak Tensions - outlookbusiness.com
Indian ADRs slump as India-Pakistan conflict sees escalation - Moneycontrol
Gift Nifty, India ADRs see sharp sell-off following escalation in India-Pakistan conflict - Moneycontrol
Dr. Reddy’s Labs Q4 FY25 Results Preview: Revenue & PAT Outlook - Samco
Validea's Top Health Care Stocks Based On Peter Lynch5/5/2025 - Nasdaq
Nomura’s top pharma bets include Dr. Reddy’s, Cipla, Lupin and Zydus - financialexpress.com
Asian ADRs See Mixed Results Despite Weekly Gains - Finimize
Dr. Reddy’s Laboratories Ltd. ADR (RDY) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Dr. Reddy’s Looks Well Positioned for Long-Term Growth, Aided by Acquisitions and Partnerships - Morningstar
Investing in Dr. Reddy’s Laboratories Ltd. ADR (RDY): What You Must Know - knoxdaily.com
Dr Reddys Share Price Highlights: Dr. Reddys Stock Price History - The Economic Times
NVO Stock Quote Price and Forecast - CNN
Zacks Industry Outlook Dr. Reddy's, Sandoz And Teva Pharmaceuticals - Barchart.com
Asian ADRs Climb, Showcasing North And South Asia Performances - Finimize
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals - Yahoo Finance
PDD Holdings Stock Delivers Phenomenal 5.82% Surge to $95.77 on April 14 – Bullish Momentum Lifts Chinese Tech - Hindustan Herald
3 Generic Drug Stocks To Watch Amid Trade War Jitters & Inflation Woes - Barchart.com
Dr Reddy’s may cut workforce by 25%, including those in Rs 1 crore bracket: Report - financialexpress.com
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):